Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07231965

Synthetic THC And Blood Pressure

To investigate the effects of Dronabinol use on blood pressure and neurovascular physiology

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Blood Pressure

Age range

21 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Recreational occasional Cannabis use (Consuming THC less than 2 times a week)
  • 21 - 40 years of age
  • Biological male or female

Exclusion criteria

  • BMI > 35 kg/m2
  • Diagnosed psychiatric disorders
  • Hypotension
  • History of seizures
  • History of substance abuse or recreational drug use or positive urine drug screen
  • History of uncontrolled disease including:
  • Cardiovascular
  • Pulmonary
  • Gastrointestinal
  • Pancreatic
  • Hepatic
  • Renal
  • Hematological
  • Endocrine (including Type I Diabetes)
  • Neurological
  • Urological
  • Sleep disorders
  • Pregnant or breastfeeding
  • Use of certain antimicrobial, chemotherapeutic, anticoagulant, hypoglycemic, anti-inflammatory, psychotropic, and antihistamine drugs
  • Prescribed CYP2C9 and/or CYP3A4 inhibitors
  • History of shift work or rotating shifts within 1 month

Treatment and study plan

Dronabinol

Drug

Patients will take one 10 mg dose of Dronabinol.

Placebo

Drug

Patients will take one 10mg dose of a Placebo Pill.

Primary outcomes

  1. Blood Pressure

    Time frame: Baseline, 30 days

    Blood pressure is the force exerted by circulating blood on the walls of the arteries as it is pumped through the body. Blood pressure will be measured as a ratio of systolic/diastolic (mmHg).

  2. Heart Rate

    Time frame: Baseline, 30 days

    Heart Rate is the number of contractions (beats) that the heart makes per minute. This will be measured in bpm (beats per minute)

Secondary outcomes

  1. Baroreflex Sensitivity

    Time frame: Baseline, 30 days

    Baroreflex sensitivity will be assessed using beat-by-beat blood pressure, heart rate, and Sympathetic nerve activity collected continuously for at least 5min. This will be measured in ms/mmHg.

  2. Sympathetic control

    Time frame: Baseline, 30 days

    Sympathetic control will be measured by microneurography of peroneal or fibular nerve, reported as bursts of sympathetic activity per minute or normalized to 100 heart beats

  3. Flow Mediated Dilation

    Time frame: Baseline, 30 days

    Flow Mediated Dilation will be measured by ultrasonography of brachial artery, reported as an absolute change in arterial diameter from resting baseline

  4. Aortic Wave Reflection

    Time frame: Baseline, 30 days

    Aortic Wave Reflection will be measured via arterial tonometry, reported as aortic augmentation index

Study contacts

Contact information is provided by the study sponsor or research team.

Nicholas Wozniak

CONTACT

[email protected]

507-255-8794

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Effects Of Cannabis Products On Blood Pressure Control

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Nov 17, 2025
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.